CDH13 and Barrett esophagus: CDH13 hypermethylation has been detected early during the neoplastic progression of BE to EAC, ranging from 0% in normal esophagus (NE) and rising to 58.3% in BE, 77.5% in BD, and 76.1% in EAC, while being rare in ESCC, and suggesting its utility as a specific biomarker for EAC.